He will follow Roel Bulthuis as the Senior Vice President and Managing Director of M Ventures. Bulthuis will be leaving the fund at the end of the year.

“What excites me most about my work for M Ventures is the active role we play in our portfolio companies, which is all about supporting our entrepreneurs in realizing their ambitions and dreams,” Bos said.

Jasper Bos joined Merck’s previous biopharma fund of M Ventures in 2009 and transitioned to Vice President leading the healthcare team for the current fund in 2016. At M Ventures, Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ-IPO), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Lundbeck for close to US$ 1.1 billion. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute.